Tumor-induced osteomalacia: An overview.

Swati Sachin Jadhav, Ravikumar Shah, Virendra Patil

Journal: Best practice & research. Clinical endocrinology & metabolism 2024;38(2):101834

PMID: 37935612

Abstract

Tumor-induced osteomalacia (TIO) is rare paraneoplastic syndrome of hypophosphatemic osteomalacia, caused by phosphaturic factors secreted by small mesenchymal origin tumors with distinct pathological features, called 'phosphaturic mesenchymal tumors'. FGF23 is the most well-characterized of the phosphaturic factors. Tumors are often small and located anywhere in the body from head to toe, which makes the localisation challenging. Functional imaging by somatostatin receptor-based PET imaging is the first line investigation, which should be followed with CT or MRI based anatomical imaging. Once localised, complete surgical excision is the treatment of choice, which brings dramatic resolution of symptoms. Medical management in the form of phosphate and active vitamin D supplements is given as a bridge to surgical management or in inoperable/non-localised patients. This review provides an overview of the epidemiology, pathophysiology, pathology, clinical features, diagnosis, and treatment of TIO, including the recent advances and directions for future research in this field.

Copyright © 2023 Elsevier Ltd. All rights reserved.

Address: Trustwell Hospital, JC road, Bangalore, Karnataka 560002, India. Electronic address: [email protected].; Harikrushna Hormone Clinic, 304, 3rd Floor, Ashwamegh, Opposite Vyamshala, Anand, Gujarat, India. Electronic address: [email protected].; Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.